SCHEMBL26089130

SCHEMBL26089130

CC(C(=O)N1CCN(Cc2ccccc2)c2ccccc21)N1CCN(C)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 3/20 0.61
▸ DRD4 P21917 1/20 0.53
▸ HSD17B10 Q99714 1/20 0.45
▸ LMNA P02545 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ ALDH1A1 P00352 2/20 0.44
▸ MAPT P10636 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ SIGMAR1 Q99720 3/20 0.44
▸ ATM Q13315 2/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.42
▸ CHRM1 P11229 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30379553 1.00 BRD4 (0.61) BRD4DRD4HSD17B10LMNAKDM4E
SCHEMBL26089051 0.92 DRD4 (0.64) BRD4DRD4LMNAKDM4EALDH1A1
SCHEMBL30379209 0.92 DRD4 (0.64) BRD4DRD4LMNAKDM4EALDH1A1
SCHEMBL26091888 0.90 DRD4 (0.52) BRD4DRD4LMNAKDM4EALDH1A1
SCHEMBL30379235 0.90 DRD4 (0.52) BRD4DRD4LMNAKDM4EALDH1A1
SCHEMBL30379566 0.90 BRD4 (0.64) BRD4DRD4LMNAKDM4EALDH1A1
SCHEMBL26090377 0.90 BRD4 (0.64) BRD4DRD4LMNAKDM4EALDH1A1
SCHEMBL30378949 0.89 BRD4 (0.62) BRD4DRD4LMNAKDM4EALDH1A1
SCHEMBL26091368 0.89 BRD4 (0.62) BRD4DRD4LMNAKDM4EALDH1A1
SCHEMBL30379691 0.87 DRD4 (0.50) BRD4DRD4LMNAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN claimed
WO-2023068755-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 사피엔스바이오 2023-04-27 — — WO claimed
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SAPIENSBIO INC. (KR) 2025-01-02 — — US disclosed
EP-4421070-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sapiensbio Inc. (KR) 2024-08-28 — — EP disclosed
CN-118119612-A Novel compounds and pharmaceutical compositions comprising the same 萨皮恩斯生物有限公司 2024-05-31 — — CN disclosed
WO-2023068755-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 사피엔스바이오 2023-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002464-A1 NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME RHOA, ACTR2, MFAP1 BRD4 371/4885DRD4 3728/4885HSD17B10 4054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback